The relation between p53 overexpression and lymph node metastases in clinical stage t2 and t3a transitional cell bladder carcinoma

Journal of Experimental and Clinical Cancer Research

Volumn 18, Issue 3, 1999, Pages 391-395

  Cemil Uygur, M ^a,b   Yaman, I ^a   Kutluay, L ^a   Altug U ^a   Erol, D ^a  

^a ANKARA NUMUNE HOSPITAL   (Turkey)

^b NONE   (Turkey)

Author keywords

Bladder cancer; Metastasis; Oncogene; P53

Indexed keywords

PROTEIN P53;

ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER SURVIVAL; CYSTECTOMY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; METASTASIS; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA;

CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; NEOPLASM PROTEINS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 2442726755     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74: 957-967, 1993.
2. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science. 253: 49-53, 1991.
3. Navone NM, Troncoso P, Pisters LL, et al: p53 protein accumulation and gene mutation in the progression of human prostate cancer. J. Natl. Canc. Inst. 85: 1657-1669, 1993.
4. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature. 351: 453-456, 1991.
5. Lipponen PK: Over-expression of p53 nuclear oncoprotein in transitional cell bladder cancer and its prognostic value. Int. J. Cancer. 53: 365-370, 1993.
6. Kuczyk MA, Serth J, Hervantin C, et al: Detection of p53 tumor-suppressor-gene protein in bladder tumors and prostate cancer: possible clinical implications. World J. Urol. 12: 345-351, 1994.
7. Esrig D, Elmajian D, Groshen S, et al: Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med. 331: 1259-1264, 1994.
8. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al: Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J. Natl. Cancer Inst. 85: 53-59, 1993.
9. Soloway MS, Lopez AE, Patel J, Lu Y: Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy. Cancer. 73: 1926-1931, 1994.
10. Smith MR, Kantoff PW: Neoadjuvant and adjuvant chemotherapy for invasive bladder cancer. Semin. Oncol. 22: 625-632, 1995.
11. Mostofi FK, Sobin LH, Torloni H: Histological typing of urinary bladder tumours. International Histological Classification of Tumours. No. 10. Geneva: World Health Organization 1973.
12. Beahrs OH, Myers MH eds, Manual for Staging of Cancer, 2nd ed. American Joint Committee on Cancer, Philadelphia: JB Lippincott, 1983: 171-173.
13. Resnick JM, Cherwitz D, Knapp D, Uhlman D, Niehans GA: A microwave method that enhances detection of aberrant p53 expression in formalin-fixed, paraffin-embedded tissues. Arch. Pathol. Lab. Med. 119: 360-366, 1995.
14. Stricker HJ, Jay JK, Linden MD, Tamboli P, Amin MB: Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53. Urology. 47: 366-369, 1996.
15. Linden MD, Nathatson SD, Zarbo RJ: Evaluation of anti-p53 antibody staining quality control and technical considerations. Appl. Immunohistochem. 2: 218-224, 1994.
16. Wu CS, Pollack A, Czerniak B, et al: WF. Prognostic value of p53 in muscle invasive bladder cancer treated with preoperative radiotherapy. Urology. 47: 305-310, 1996.
17. Thomas DJ, Robinson MC, Charlton R, Wilkinson S, Shenton BK, Neal DE: p53 expression, ploidy and progression in pt1 transitional cell carcinoma of the bladder. Br. J. Urol. 73: 533-537, 1994.
18. Wright C, Mellon K, Johnston P, Harris AL, Home CHW: Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br. J. Cancer. 63: 967-970, 1991.
19. Cordon-Cardo C, Dalbagni G, Saez GT, et al: p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int. J. Cancer. 56: 347-353, 1994.
20. Prout GR, Griffin PP, Shipley WU: Bladder cancer as a systemic disease. Cancer. 43: 2532-2539, 1979.
21. Pollack A, Zagars GK, Cole CJ, Dinney CPN, Swanson DA, Grossman HB: The relationship of local control to distant metastasis in muscle invasive bladder cancer. J. Urol. 154: 2059-2064, 1995.
22. Tsuji M, Kojima K, Murakami Y, Kanayama H, Kagawa S: Prognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: immunohistochemical analysis of radical cystectomy specimens. Br. J. Urol. 79: 367-372, 1997.
23. Scher HI, Norton L: Chemotherapy for urotelyal tract malignancies: breaking the deadlock. Semin. Surg. Oncol. 8: 316-341, 1992.
24. Mellon K, Wilkinson S, Vickers J, Robinson MC, Shenton BK, Neal DE: Abnormalities in p53 and DNA content in transitional cell carcinoma of the bladder. Br. J. Urol. 73: 522-524, 1994.
25. Lane DP: p53, guardian of the genome. Nature. 358: 15-16, 1992.